4
Changes in Ownership
Entrada Therapeutics, Inc. Filed Acc 0001689375-23-000061
Chief Operating Officer sold 972 shares at an average $13.47 ($13,089)
- Chief Operating Officer gave up 436 shares (to pay taxes)
- Chief Operating Officer acquired 14,200 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Dowden Nathan J Chief Operating Officer | 2023-09-01 | Grant or award 10b5-1 | +14,200 | 49,576 | D: show line 1 in the form | ||
| Dowden Nathan J Chief Operating Officer | 2023-09-05 | Shares withheld for taxes 10b5-1 | −436 | $14.46 | $6,306 | 49,140 | D: show line 2 in the form |
| Dowden Nathan J Chief Operating Officer | 2023-09-06 | Sale 10b5-1 | −913 | $13.43 | $12,263 | 48,227 | D: show line 3 in the form |
| Dowden Nathan J Chief Operating Officer | 2023-09-06 | Sale 10b5-1 | −59 | $14.01 | $826 | 48,168 | D: show line 4 in the form |
| Open-market sales · 972 sh · avg $13.47 · $13,089 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Dowden Nathan J Chief Operating Officer | 2023-09-01 | Grant or award · Stock Option (Right to Buy) 10b5-1 | +21,500 | 21,500 | D: show line 5 in the form |
Loading xslF345X05/wf-form4_169403443743456.xml…